Saybrook Capital NC Sells 4,172 Shares of Johnson & Johnson (NYSE:JNJ)

Saybrook Capital NC decreased its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 75,769 shares of the company’s stock after selling 4,172 shares during the quarter. Johnson & Johnson makes up about 4.4% of Saybrook Capital NC’s portfolio, making the stock its 9th biggest holding. Saybrook Capital NC’s holdings in Johnson & Johnson were worth $13,385,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Glassy Mountain Advisors Inc. purchased a new stake in Johnson & Johnson in the 4th quarter valued at about $35,000. Retirement Financial Solutions LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth about $40,000. TD Capital Management LLC purchased a new stake in Johnson & Johnson during the third quarter worth about $48,000. VitalStone Financial LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth about $52,000. Finally, Iron Horse Wealth Management LLC increased its stake in Johnson & Johnson by 112.8% during the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock worth $53,000 after purchasing an additional 159 shares during the period. Institutional investors and hedge funds own 67.94% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $160.78 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85. The stock has a fifty day moving average price of $159.10 and a 200 day moving average price of $166.76. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $183.35. The company has a market cap of $417.82 billion, a PE ratio of 33.64, a P/E/G ratio of 2.77 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The firm had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. During the same period last year, the company earned $2.67 earnings per share. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. Sell-side analysts forecast that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. The ex-dividend date of this dividend is Monday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a dividend yield of 2.96%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 94.56%.

Analyst Ratings Changes

A number of brokerages have issued reports on JNJ. StockNews.com began coverage on shares of Johnson & Johnson in a research note on Thursday, March 16th. They set a “strong-buy” rating on the stock. Atlantic Securities cut their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 19th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 1st. SVB Leerink cut their target price on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research note on Friday, January 20th. Finally, Guggenheim initiated coverage on Johnson & Johnson in a report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price target for the company. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $173.00.

Insiders Place Their Bets

In other news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the transaction, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.20% of the stock is currently owned by company insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.